Six forces shaping pharmaceutical demand in Pakistan right now. Understanding these makes your forecasts more accurate.
P
DRAP controls what you produce, how you label it, and what price you can charge. Government is pushing local pharma manufacturing — a real opportunity. But frequent drug pricing policy changes make long-term planning difficult.
E
Over 80% of Pakistan's pharmaceutical raw materials (APIs) are imported from China and India. PKR devaluation has significantly raised input costs. Export to the Middle East and Africa is growing and offers a dollar-earning hedge against local pressures.
S
Demand is driven by Pakistan's endemic disease burden: dengue (Jul–Oct), typhoid, and TB create consistent demand for antibiotics and antipyretics. Ramadan drives multivitamin purchases. An urbanising middle class is shifting toward branded medicines.
T
WHO-GMP compliance is increasingly required by export markets and hospital buyers. Automated quality monitoring reduces batch rejection rates. Cold chain improvements are opening rural markets for temperature-sensitive products.
L
DRAP registration for new products takes 12–24 months — plan accordingly. Scheduled drug regulations restrict over-the-counter sales. Drug pricing for essential medicines is partially government-controlled, limiting margin flexibility on core products.
E
Load shedding directly threatens temperature-controlled pharmaceutical manufacturing. Monsoon flooding disrupts API supply chains more frequently every year. Rising temperatures boost dengue and gastroenteritis cases — but the same heat strains cold storage infrastructure.